Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding
A multicenter prospective study reveals a higher incidence but very low burden of new-onset atrial fibrillation post-CABG, challenging current anticoagulation guidelines.
Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti
The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.
A 75-year-old male on warfarin presented with spontaneous thigh swelling and pain, diagnosed as spontaneous intramuscular hematoma, successfully managed with supportive care and warfarin reversal.
Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.
This study found no overall advantage of anticoagulation over antiplatelet therapy in ESUS patients but identified a potential benefit of anticoagulation in those with left ventricular injury.
Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remain
The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.